Developments in Pain Imaging
Journal Title: Nuclear Medicine Seminars - Year 2020, Vol 6, Issue 1
Abstract
In order to determine the etiology of chronic pain, radiological imaging tools like computed tomography (CT) and magnetic resonance imaging (MRI) are usually used. Except for the anatomical data that the radiological imaging methods provide, there are nuclear medicine imaging methods like bone scintigraphy and positron emission tomography (PET) which are used to demonstrate metabolic changes in the bone, joint and neighbouring soft tissue which may cause pain. Recently, hybrid imaging methods combining anatomical and metabolic imaging like single photon emission computed tomography (SPECT)/CT and PET/MR have been introduced. In the last decades, imaging with higher resolution and providing anatomical localisation have been possible thanks to bone scintigraphy performed with hybrid SPECT/CT. This is why clinical studies have been performed especially about the role of bone SPECT/CT in the evaluation of pain originating from vertebra. The major limitation of the studies with bone SPECT/CT is that the uptake of radiopharmaceutical is limited to increase in osteoblastic activity and that changes like inflammation cannot be diagnosed. So, PET imaging combined with MR and performed with radiopharmaceuticals imaging different metabolic pathways come forward. PET/MR studies performed with the most commonly used radiopharmaceutical, F-18-FDG, come first among the studies on PET/MR in pain imaging. While F-18-FDG PET/MR imaging provides anatomical abnormalities of the joint with MRI component and hypermetabolic/inflammatory pathologies with PET component, it is a promising imaging tool for diagnosing the causes of chronic pain. Another PET radiopharmaceutical in pain imaging is F-18-sodyum fluoride (NaF). However, data about its use in degenerative bone diseases is limited. It has been reported that metabolic changes can be detected before MRI changes appear. Sigma-1 receptor (S1R) is especially localized in the endoplasmic reticulum as a signal modulating receptor which plays role in the pathophysiology of many neurological diseases, mainly neuropathic pain, is found extensively in the central nervous system. F-18- FTC-146 [6-(3-(18F)fluoropropyl)-3-(2-(azepan-1)ethyl)benzo(d)thiazol-2] is a radiopharmaceutical which targets this receptor and binds with high affinity. Because it is a very recently developed radiopharmaceutical, the available findings are needed to be supported by further clinical trials. Already existing results show that this imaging method is a promising tool in pain imaging.
Authors and Affiliations
Çiğdem Soydal, Mine Araz
Keywords
Related Articles
- EP ID EP685342
- DOI 10.4274/nts.galenos.2020.0001
- Views 169
- Downloads 0
Essentials of Thyroid Hormone Treatment in Differentiated Thyroid Cancer
Levothyroxine is used for both hormone replacement and suppression of thyroid stimulating hormone (TSH) secretion from pituitary gland at supraphysiological doses in differentiated thyroid cancer (DTC). The impact of TSH...
Oncologic Approaches for Bone Metastasis Related Pain
Bone is the third most common metastatic site after lungs and liver in advanced stages of cancer. Bone pain may be caused by local compression and/or invasion of the tumor or a pathological fracture due to bone metastasi...
Good Radiopharmacy Practices In Magistral (or Inhouse or Smallscale) Produced Radiopharmaceuticals
Radiopharmaceuticals differ from normal medicines in that they have a short half-life. Due to the rapid decay, they must be prepared shortly before their clinical use and comprehensive quality control of the final produc...
Renal Cortical Scintigraphy Procedure Guideline
This guideline is the updated version of TNTD renal cortical scintigraphy guideline published in 2001. It includes the current recommended patient doses and patient dosimetry according to international guidelines.
Renal Toxicity After Radionuclide Therapy
With the introduction of radionuclide therapies, the probability of toxicity has increased in critical organs such as kidney and bone marrow. Although these toxicity rates are relatively low in targeted therapies such as...